Myelin and Lymphocyte Protein 2 Regulates Cell Proliferation and Metastasis Through the Notch Pathway in Prostate Adenocarcinoma

Overview

Journal Transl Androl Urol

Date 2021 Jun 23

PMID 34159087

Citations 8

Authors

Chenglong Zheng

Ji Wang

Jian Zhang

Shujuan Hou

Yanfei Zheng

Qi Wang

Affiliations

Soon will be listed here.

Abstract

Background: Myelin and lymphocyte protein 2 (MAL2) is a proven oncogene in some human tumors. However, currently, little is known about the function of MAL2 in prostate adenocarcinoma (PRAD). This study sought to investigate the role of MAL2 on PRAD progression.

Methods: MAL2 expression in PRAD was first analyzed by the Gene Expression Profiling Interactive Analysis (GEPIA) database. The reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay and Western blot assay were used to detect the expression of MAL2 in PRAD tissues and cell lines. Additionally, immunohistochemistry (IHC) straining was used to detect the expression of MAL2 in PRAD pathological tissues. The Cell Counting Kit-8 (CCK-8) assay, clone formation assay and Flow cytometry were performed to investigate the effect of MAL2 on PRAD cell proliferation and cell apoptosis. Cell migration and invasion were measured by Transwell assay. The effect of MAL2 on epithelial-mesenchymal transition (EMT) progression and the Notch signaling pathway in PRAD was also investigated.

Results: MAL2 was discovered to be obviously upregulated in PRAD tissues and cell lines. The upregulation of MAL2 was closely associated with tumor, nodes and metastases (TNM) stage, the Gleason score and metastasis of PRAD patients, and affected the prognosis of PRAD patients. Functionally, the depletion of MAL2 suppressed cell proliferation, migration, invasion, and EMT progression, and promoted cell apoptosis of PRAD cells. In an experiment, MAL2 knockdown significantly suppressed tumor growth in mice. Further, inhibiting the Notch pathway reversed the effect of MAL2 knockdown on PRAD progression.

Conclusions: In sum, MAL2 was found to be upregulated in PRAD, and appears to act as a carcinogen in PRAD. Additionally, MAL2 appears to regulate PRAD progression through the Notch signaling pathway.

Citing Articles

High MAL2 expression predicts shorter survival in women with triple-negative breast cancer.

Borowczak J, Zdrenka M, Socha W, Gostomczyk K, Szczerbowski K, Maniewski M Clin Transl Oncol. 2024; 26(10):2549-2558.

PMID: 38769215 PMC: 11410892. DOI: 10.1007/s12094-024-03514-4.

Research advances of MAL family members in tumorigenesis and tumor progression (Review).

Li M, Du Y, Zhang X, Zhou W Mol Med Rep. 2024; 29(4).

PMID: 38362940 PMC: 10884788. DOI: 10.3892/mmr.2024.13181.

Downregulation of MAL2 inhibits breast cancer progression through regulating β-catenin/c-Myc axis.

An L, Gong H, Yu X, Zhang W, Liu X, Yang X Cancer Cell Int. 2023; 23(1):144.

PMID: 37480012 PMC: 10362617. DOI: 10.1186/s12935-023-02993-9.

The MAL Family of Proteins: Normal Function, Expression in Cancer, and Potential Use as Cancer Biomarkers.

Labat-de-Hoz L, Rubio-Ramos A, Correas I, Alonso M Cancers (Basel). 2023; 15(10).

PMID: 37345137 PMC: 10216460. DOI: 10.3390/cancers15102801.

Identifying Genes that Affect Differentiation of Human Neural Stem Cells and Myelination of Mature Oligodendrocytes.

Ye D, Wang Q, Yang Y, Chen B, Zhang F, Wang Z Cell Mol Neurobiol. 2022; 43(5):2337-2358.

PMID: 36547781 PMC: 10287785. DOI: 10.1007/s10571-022-01313-5.

References

Reiff T, Baeumers M, Tibbe C, Klein T . Unravelling of Hidden Secrets: The Tumour Suppressor Lethal (2) Giant Discs (Lgd)/CC2D1, Notch Signalling and Cancer. Adv Exp Med Biol. 2020; 1287:31-46. DOI: 10.1007/978-3-030-55031-8_3. View

Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z . MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2020; 131(1). PMC: 7773365. DOI: 10.1172/JCI140837. View

Fasoulakis Z, Daskalakis G, Theodora M, Antsaklis P, Sindos M, Diakosavvas M . The Relevance of Notch Signaling in Cancer Progression. Adv Exp Med Biol. 2020; 1287:169-181. DOI: 10.1007/978-3-030-55031-8_11. View

Miller K, Nogueira L, Mariotto A, Rowland J, Yabroff K, Alfano C . Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69(5):363-385. DOI: 10.3322/caac.21565. View

Wilson S, Bailey A, Nourse C, Mattei M, Byrne J . Identification of MAL2, a novel member of the mal proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics. 2001; 76(1-3):81-8. DOI: 10.1006/geno.2001.6610. View

Li J, Li Y, Liu H, Liu Y, Cui B . The four-transmembrane protein MAL2 and tumor protein D52 (TPD52) are highly expressed in colorectal cancer and correlated with poor prognosis. PLoS One. 2017; 12(5):e0178515. PMC: 5451064. DOI: 10.1371/journal.pone.0178515. View

De Marco M, Martin-Belmonte F, Kremer L, Albar J, Correas I, Vaerman J . MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. J Cell Biol. 2002; 159(1):37-44. PMC: 2173496. DOI: 10.1083/jcb.200206033. View

Misiorek J, Przybyszewska-Podstawka A, Kalafut J, Paziewska B, Rolle K, Rivero-Muller A . Context Matters: NOTCH Signatures and Pathway in Cancer Progression and Metastasis. Cells. 2021; 10(1). PMC: 7827494. DOI: 10.3390/cells10010094. View

Deng G, Ma L, Meng Q, Ju X, Jiang K, Jiang P . Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology. J Cancer Res Clin Oncol. 2015; 142(3):531-47. DOI: 10.1007/s00432-015-1946-x. View

10.

Monticone G, Miele L . Notch Pathway: A Journey from Notching Phenotypes to Cancer Immunotherapy. Adv Exp Med Biol. 2020; 1287:201-222. DOI: 10.1007/978-3-030-55031-8_13. View

11.

Aranda J, Reglero-Real N, Marcos-Ramiro B, Ruiz-Saenz A, Fernandez-Martin L, Bernabe-Rubio M . MYADM controls endothelial barrier function through ERM-dependent regulation of ICAM-1 expression. Mol Biol Cell. 2012; 24(4):483-94. PMC: 3571871. DOI: 10.1091/mbc.E11-11-0914. View

12.

In J, Tuma P . MAL2 selectively regulates polymeric IgA receptor delivery from the Golgi to the plasma membrane in WIF-B cells. Traffic. 2010; 11(8):1056-66. PMC: 2904422. DOI: 10.1111/j.1600-0854.2010.01074.x. View

13.

Dimakakos A, Armakolas A, Koutsilieris M . Novel tools for prostate cancer prognosis, diagnosis, and follow-up. Biomed Res Int. 2014; 2014:890697. PMC: 4024423. DOI: 10.1155/2014/890697. View

14.

In J, Striz A, Bernad A, Tuma P . Serine/threonine kinase 16 and MAL2 regulate constitutive secretion of soluble cargo in hepatic cells. Biochem J. 2014; 463(2):201-13. PMC: 4736628. DOI: 10.1042/BJ20140468. View

15.

Fanayan S, Shehata M, Agterof A, McGuckin M, Alonso M, Byrne J . Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. BMC Cell Biol. 2009; 10:7. PMC: 2644682. DOI: 10.1186/1471-2121-10-7. View

16.

Serrell E, Pitts D, Hayn M, Beaule L, Hansen M, Sammon J . Review of the comparative effectiveness of radical prostatectomy, radiation therapy, or expectant management of localized prostate cancer in registry data. Urol Oncol. 2017; 36(4):183-192. DOI: 10.1016/j.urolonc.2017.10.003. View

17.

Gao X, Chen Z, Li A, Zhang X, Cai X . MiR-129 regulates growth and invasion by targeting MAL2 in papillary thyroid carcinoma. Biomed Pharmacother. 2018; 105:1072-1078. DOI: 10.1016/j.biopha.2018.06.050. View

18.

Shao B, Fu X, Li X, Li Y, Gan N . RP11-284F21.9 promotes oral squamous cell carcinoma development via the miR-383-5p/MAL2 axis. J Oral Pathol Med. 2019; 49(1):21-29. DOI: 10.1111/jop.12946. View

19.

Kimura T, Egawa S . Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018; 25(6):524-531. DOI: 10.1111/iju.13593. View

20.

Fujizuka Y, Ito K, Oki R, Suzuki R, Sekine Y, Koike H . Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL. Int J Urol. 2017; 24(8):602-609. DOI: 10.1111/iju.13381. View